Results 11 to 20 of about 1,190,584 (342)
Non-small-cell lung cancer [PDF]
Nature Reviews Disease Primers, 2015 Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous class of tumours, represents approximately 85% of all new lung cancer diagnoses. Tobacco smoking remains the main risk factor for developing this disease, but radon exposure and air ...
Gridelli, C +8 more
+7 more sources
Non-small cell lung cancer [PDF]
BMJ, 2012 This patient describes his experience of multidisciplinary care after his diagnosis of non-small cell lung cancer when he was 15 years ...
Andrew, Hill +2 more
+6 more sources
Non-small cell lung cancer [PDF]
Vnitřní lékařství, 2017 Non-small cell lung cancer (NSCLC) represents 80 % of diseases considering all patients with lung cancer. NSCLC comprises all histological types except for the small cell cancer. The treatment is chosen based on a clinical stage, morphological diagnosis and performance status of patients. In the low clinical stages a surgical solution is indicated.
Jana, Skřičková +2 more
openaire +2 more sources
LncRNAs in Non-Small-Cell Lung Cancer [PDF]
Non-Coding RNA, 2020 Lung cancer is associated with a high mortality, with around 1.8 million deaths worldwide in 2018. Non-small-cell lung cancer (NSCLC) accounts for around 85% of cases and, despite improvement in the management of NSCLC, most patients are diagnosed at advanced stage and the five-year survival remains around 15%.
Lucy Ginn +3 more
openaire +4 more sources
MicroRNA-24 in Cancer: A Double Side Medal With Opposite Properties
Frontiers in Oncology, 2020 MicroRNA-24 (miR-24) has been widely studied in a variety of human cancers, which plays different roles in specific type of cancers. In the present review, we summarized the recent surveys regarding the role of miR-24 in different human cancers.
Sumei Wang +18 more
doaj +1 more source
Non-small-cell lung cancer: how to manage BRAF-mutated disease
Drugs in Context, 2023 BRAF mutations are reported in about 3–5% of non-small-cell lung cancer (NSCLC), almost exclusively in adenocarcinoma histology, and are classified into three different classes. The segmentation of BRAF mutations into V600 (class 1) and non-V600 (classes
Giorgia Guaitoli +5 more
doaj +1 more source
Non‐small cell lung cancer in China
Cancer Communications, 2022 In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early‐stage non‐small cell lung cancer
Peixin Chen +3 more
doaj +1 more source
Non-small-cell lung cancer: how to manage RET-positive disease
Drugs in Context, 2022 Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC). RET rearrangements are typically observed in about 1–2% of NSCLC, resulting in constitutive activation of downstream signalling ...
Elisa Andrini +6 more
doaj +1 more source
Overexpression of the non-coding SOX2OT variants 4 and 7 in lung tumors suggests an oncogenic role in lung cancer [PDF]
, 2016 Despite the advances in cancer therapy, lung cancer still remains the most leading cause of cancer death worldwide. The long non-coding RNAs (lncRNAs) are recently introduced as novel regulators of human cancers. SOX2 overlapping transcript (SOX2OT) is a
Ghanei, M. +4 more
core +1 more source
Non-small-cell lung cancer: how to manage EGFR-mutated disease
Drugs in Context, 2022 The treatment of non-small-cell lung cancer (NSCLC) harbouring EGFR mutations has witnessed some major breakthroughs in the last years. On the one hand, the recent advent of the third-generation tyrosine kinase inhibitor (TKI) osimertinib has reshaped ...
Federica Pecci +6 more
doaj +1 more source